Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.
Identifieur interne : 000014 ( PubMed/Checkpoint ); précédent : 000013; suivant : 000015Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.
Auteurs : Sara L. Gale [États-Unis] ; Huong Trinh [États-Unis] ; Nitya Mathew [États-Unis] ; Angelika Jahreis [États-Unis] ; Celia J F. Lin [États-Unis] ; Khaled Sarsour [États-Unis]Source :
- Rheumatology and therapy [ 2198-6576 ] ; 2020.
Abstract
Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignment with SSc disease manifestations.
DOI: 10.1007/s40744-019-00181-8
PubMed: 31734871
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31734871Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.</title><author><name sortKey="Gale, Sara L" sort="Gale, Sara L" uniqKey="Gale S" first="Sara L" last="Gale">Sara L. Gale</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA. gale.sara@gene.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Trinh, Huong" sort="Trinh, Huong" uniqKey="Trinh H" first="Huong" last="Trinh">Huong Trinh</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mathew, Nitya" sort="Mathew, Nitya" uniqKey="Mathew N" first="Nitya" last="Mathew">Nitya Mathew</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jahreis, Angelika" sort="Jahreis, Angelika" uniqKey="Jahreis A" first="Angelika" last="Jahreis">Angelika Jahreis</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lin, Celia J F" sort="Lin, Celia J F" uniqKey="Lin C" first="Celia J F" last="Lin">Celia J F. Lin</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31734871</idno><idno type="pmid">31734871</idno><idno type="doi">10.1007/s40744-019-00181-8</idno><idno type="wicri:Area/PubMed/Corpus">000022</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000022</idno><idno type="wicri:Area/PubMed/Curation">000022</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000022</idno><idno type="wicri:Area/PubMed/Checkpoint">000014</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000014</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.</title><author><name sortKey="Gale, Sara L" sort="Gale, Sara L" uniqKey="Gale S" first="Sara L" last="Gale">Sara L. Gale</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA. gale.sara@gene.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Trinh, Huong" sort="Trinh, Huong" uniqKey="Trinh H" first="Huong" last="Trinh">Huong Trinh</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mathew, Nitya" sort="Mathew, Nitya" uniqKey="Mathew N" first="Nitya" last="Mathew">Nitya Mathew</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jahreis, Angelika" sort="Jahreis, Angelika" uniqKey="Jahreis A" first="Angelika" last="Jahreis">Angelika Jahreis</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lin, Celia J F" sort="Lin, Celia J F" uniqKey="Lin C" first="Celia J F" last="Lin">Celia J F. Lin</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><affiliation wicri:level="2"><nlm:affiliation>, Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>, Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Rheumatology and therapy</title><idno type="ISSN">2198-6576</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignment with SSc disease manifestations.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31734871</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2198-6576</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Rheumatology and therapy</Title><ISOAbbreviation>Rheumatol Ther</ISOAbbreviation></Journal><ArticleTitle>Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.</ArticleTitle><Pagination><MedlinePgn>89-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40744-019-00181-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignment with SSc disease manifestations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Treatment patterns and disease manifestations, symptoms, complications, and comorbidities were assessed in patients with SSc enrolled in a US healthcare claims database who received treatment between January 2006 and December 2013 and for whom data were available 6 months before and 12 months after SSc diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 7812 eligible patients, 6852 received treatments of interest for SSc and 2404 (30.8%) received IMT during the first year after SSc diagnosis. In the first year after diagnosis, the most common claims were for antibiotics (61.7%), opioids (50.6%), glucocorticoids (46.5%), and proton pump inhibitors (35.4%); the most common organs involved with complications among patients with SSc were lung (30.5%), heart (17.4%), and gastrointestinal tract (22.4%); the most common signs or symptoms were musculoskeletal (16.1%) and fatigue (10.5%); 1035 patients (15.1%) had infections and 14 (0.2%) had malignancies. Among patients who received IMT, 43.8% received at least hydroxychloroquine and 21.1% received at least methotrexate; 460 patients switched to a second IMT, 23.0% to at least methotrexate and 22.8% to at least mycophenolate mofetil. The most common comorbidities reported with first IMT were in lung (11.8%), overlap syndrome (8.4%), heart (5.3%), and gastrointestinal (6.8%) categories.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">One-third of patients with SSc in the healthcare claims population received IMTs during the first year after diagnosis. However, patients who received IMTs had disease manifestations similar to those of the overall SSc healthcare claims population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gale</LastName><ForeName>Sara L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7556-8990</Identifier><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA. gale.sara@gene.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Huong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Nitya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahreis</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Celia J F</ForeName><Initials>CJF</Initials><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarsour</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatol Ther</MedlineTA><NlmUniqueID>101674543</NlmUniqueID><ISSNLinking>2198-6576</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Databases</Keyword><Keyword MajorTopicYN="N">Immunosuppressive agents</Keyword><Keyword MajorTopicYN="N">Patterns of care</Keyword><Keyword MajorTopicYN="N">Scleroderma</Keyword><Keyword MajorTopicYN="N">Systemic sclerosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31734871</ArticleId><ArticleId IdType="doi">10.1007/s40744-019-00181-8</ArticleId><ArticleId IdType="pii">10.1007/s40744-019-00181-8</ArticleId><ArticleId IdType="pmc">PMC7021840</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2016 Jun 25;387(10038):2630-2640</Citation><ArticleIdList><ArticleId IdType="pubmed">27156934</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rheum Dis Clin North Am. 2003 May;29(2):239-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12841293</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arthritis Rheum. 2003 Aug;48(8):2246-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12905479</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2014 Jun 25;311(24):2490-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25058083</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Intern Med J. 2001 May-Jun;31(4):220-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11456035</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Rheumatol. 2012 Mar;39(3):524-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22247347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Des Devel Ther. 2016 Aug 29;10:2723-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27621593</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mayo Clin Proc. 2013 Apr;88(4):377-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23541012</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arthritis Rheum. 2001 Jun;44(6):1351-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11407694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Best Pract Res Clin Rheumatol. 2010 Dec;24(6):857-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21665131</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Rheumatol. 2014 Mar-Apr;32(2 Suppl 81):156-64</Citation><ArticleIdList><ArticleId IdType="pubmed">24742450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2019 Jun 27;380(26):2518-2528</Citation><ArticleIdList><ArticleId IdType="pubmed">31112379</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Br J Rheumatol. 1988 Aug;27(4):286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">3261609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2011 Aug 6;378(9790):498-506</Citation><ArticleIdList><ArticleId IdType="pubmed">21777972</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Med. 2005 Jan;118(1):2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15639201</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2006 Jun 22;354(25):2655-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16790698</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Rheumatol. 2018 Oct;45(10):1406-1410</Citation><ArticleIdList><ArticleId IdType="pubmed">30008448</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Semin Arthritis Rheum. 2017 Apr;46(5):625-631</Citation><ArticleIdList><ArticleId IdType="pubmed">27839742</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2009 May;68(5):620-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19147617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2016 Sep;4(9):708-719</Citation><ArticleIdList><ArticleId IdType="pubmed">27469583</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Rheum Dis. 1994 Aug;53(8):502-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7944633</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Semin Arthritis Rheum. 2008 Feb;37(4):223-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17692364</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Medicine (Baltimore). 2008 Sep;87(5):272-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18794710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Semin Arthritis Rheum. 2012 Aug;42(1):42-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22464314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arthritis Rheum. 2006 Dec;54(12):3962-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17133610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Rheumatol. 2012 Apr;39(4):784-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22382343</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rheumatology (Oxford). 2012 Sep;51(9):1600-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22539477</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2017 Aug;76(8):1327-1339</Citation><ArticleIdList><ArticleId IdType="pubmed">27941129</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arthritis Res Ther. 2010;12(2):R54</Citation><ArticleIdList><ArticleId IdType="pubmed">20338043</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rheumatology (Oxford). 2016 Oct;55(10):1906-10</Citation><ArticleIdList><ArticleId IdType="pubmed">27284161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2014 Oct;73(10):1788-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23897770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Gale, Sara L" sort="Gale, Sara L" uniqKey="Gale S" first="Sara L" last="Gale">Sara L. Gale</name></region><name sortKey="Jahreis, Angelika" sort="Jahreis, Angelika" uniqKey="Jahreis A" first="Angelika" last="Jahreis">Angelika Jahreis</name><name sortKey="Lin, Celia J F" sort="Lin, Celia J F" uniqKey="Lin C" first="Celia J F" last="Lin">Celia J F. Lin</name><name sortKey="Mathew, Nitya" sort="Mathew, Nitya" uniqKey="Mathew N" first="Nitya" last="Mathew">Nitya Mathew</name><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><name sortKey="Trinh, Huong" sort="Trinh, Huong" uniqKey="Trinh H" first="Huong" last="Trinh">Huong Trinh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31734871
|texte= Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31734871" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |